hourglass_emptyLongevityOpioid-receptor modulator (non-peptide)

Low-Dose Naltrexone

Also known as LDN

Non-peptide adjunct: compounded microdoses of naltrexone studied for inflammatory modulation, recovery quality, and chronic symptom support.

Compounded medications are not FDA-approved and are not the same as brand-name products.

Discuss with a physician Browse all peptides

Mechanism of action

How Low-Dose Naltrexone works

Transient low-dose opioid-receptor blockade upregulates endogenous endorphin signaling and modulates glial and immune activity, distinct from full-dose naltrexone therapy.

Areas of study

What Low-Dose Naltrexone is studied for

check
Inflammatory and pain modulation in chronic conditions
check
Adjunctive support in autoimmune and fatigue contexts
check
Sleep and recovery quality

Considerations

Important things your physician will discuss

This is general clinical context — not medical advice. Your evaluation determines whether Low-Dose Naltrexone is appropriate for you.

info
Incompatible with opioid medications — combining can precipitate withdrawal; disclose all current prescriptions
info
Compounded low-dose strengths differ from the FDA-approved 50 mg tablet and its labeled indications
info
Vivid dreams or transient sleep changes are common in the first weeks of therapy

Used in